Stock Analysis
Nutriplant Indústria e Comércio S/A Full Year 2023 Earnings: EPS: R$0.26 (vs R$0.63 in FY 2022)
Nutriplant Indústria e Comércio S/A (BVMF:NUTR3) Full Year 2023 Results
Key Financial Results
- Revenue: R$179.1m (up 2.4% from FY 2022).
- Net income: R$3.51m (down 58% from FY 2022).
- Profit margin: 2.0% (down from 4.8% in FY 2022). The decrease in margin was driven by higher expenses.
- EPS: R$0.26 (down from R$0.63 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nutriplant Indústria e Comércio S/A shares are down 4.2% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Nutriplant Indústria e Comércio S/A (1 is potentially serious!) that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Nutriplant Indústria e Comércio S/A is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BOVESPA:NUTR3
Nutriplant Indústria e Comércio S/A
Nutriplant Indústria e Comércio S/A develops, produces, and sells special fertilizers and micronutrients to agribusiness in Brazil.
Excellent balance sheet and fair value.